Reports Q4 revenue $430M, consensus $379.42M. “2024 marked the completion of a multi-year effort to transition the business into a highly ...

Avadel Pharmaceuticals' stock is undervalued due to peak sales potential, along with the possibility of a buyout. Click here ...

Methods: Among 530 patients with a post-COVID condition, those with excessive daytime sleepiness were systematically assessed for objective central hypersomnia, with exclusion of all cases not clearly ...

Since launching in 2017, Plymouth Meeting’s Harmony Biosciences has grown from a small drug developer into a billion-dollar company, writes John ...

Nearly all study participants indicated that idiopathic hypersomnia negatively affected their social lives. The vast majority of individuals with idiopathic hypersomnia report that their disorder ...

Like millions of other Americans, Kelsey Hameister's mood is impacted by the change of seasons. Two in every five say their ...

Equities research analysts at Roth Capital issued their FY2029 earnings per share estimates for Zevra Therapeutics in a note issued to investors on Sunday, February 9th. Roth Capital analyst J.

Deutsche Bank (ETR:DBKGn) initiated coverage on Alkermes (NASDAQ:ALKS) shares with a Buy rating and a price target of $40.00.

Patients: 26 narcoleptic patients with cataplexy, 9 narcoleptic patients without cataplexy, 2 patients with abnormal REM-sleep-associated hypersomnia, 7 patients with idiopathic hypersomnia, 2 ...

This was highlighted by Dr Sermed Mezher in a recent reel posted on Instagram, “People with KLS experience recurring episodes where they sleep excessively, sometimes up to 20 hours a day, for weeks at ...

“Ironically, too much sleep can also mess with your body’s natural rhythms, leading to trouble falling or staying asleep at ...